Nicotinamide Mononucleotide, Reduced Form (NMNH)

World's First, Largest, and Longest Human Clinical Trial on NMNH (Reduced NMN)

Product Name: β-Nicotinamide Mononucleotide, reduced form (NMNH)

CAS No. : 4229-56-5

Phase I clinical trial result has shown UthPeak® NMNH (Reduced NMN) effects on

l  3X NAD+ INCREMENT

l  5 Years YOUGNER

l  35% Boost in ENERGY

l  31% Improvement in EMOTIONAL WELLNESS

UthPeak® has recently obtained the self-affirmed GRAS status for use in selected conventional foods, cellular health supplements, and medical foods.

Why UthPeak® NMNH

Preclinical and clinical studies to ensure safety and efficacy

EffePharm has been dedicated to delivering safe and clinically-backed ingredients top nmn supplements. To ensure the safety of UthPeak® NMNH, comprehensive preclinical toxicology studies have been conducted. UthPeak® is the first NMNH brand globally to conduct the largest and longest human clinical trial on NMNH (reduced NMN).

UthPeak® NMNH Clinical Agenda

UthPeak® NMNH (reduced NMN) has completed a 90-day Phase I clinical trial with 80 healthy participants, demonstrating promising safety, increased NAD+ levels, and reduced biological age indicators, along with improved emotional well-being and energy support.
The forthcoming phase II UthPeak® clinical trials in 2025 will concentrate on assessing NMNH’s potential to enhance consumer-centric well-being factors such as cardioprotection, neuroprotection, and liver protection.

Preclinical Studies

The completion of extensive animal studies has underscored the potential of UthPeak® in various areas of health and wellness.

The ingredient has shown promising results in:

l  ANTI-FATIGUE

l  SLEEP QUALITY IMPROVEMENT

l  CARDIOVASCULAR HEALTH PROMOTION

l  BRAIN FUNCTION ENHANCEMENT

l  ANTI-AGING